[go: up one dir, main page]

MX2023011240A - Composiciones farmaceuticas que comprenden zolmitriptan. - Google Patents

Composiciones farmaceuticas que comprenden zolmitriptan.

Info

Publication number
MX2023011240A
MX2023011240A MX2023011240A MX2023011240A MX2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A
Authority
MX
Mexico
Prior art keywords
zolmitriptan
pharmaceutical compositions
treatment
aggression
dementia
Prior art date
Application number
MX2023011240A
Other languages
English (en)
Inventor
Michael Wood
James Lillie
Original Assignee
Maplight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc filed Critical Maplight Therapeutics Inc
Publication of MX2023011240A publication Critical patent/MX2023011240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporciona una composición oral que comprende zolmitriptán y métodos de uso de ella, por ejemplo, para el tratamiento de los síntomas del trastorno del espectro autista y para el tratamiento de la agresión en pacientes con demencia.
MX2023011240A 2021-03-25 2022-03-24 Composiciones farmaceuticas que comprenden zolmitriptan. MX2023011240A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US202263306377P 2022-02-03 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (1)

Publication Number Publication Date
MX2023011240A true MX2023011240A (es) 2024-01-12

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011240A MX2023011240A (es) 2021-03-25 2022-03-24 Composiciones farmaceuticas que comprenden zolmitriptan.

Country Status (10)

Country Link
US (1) US20240189240A1 (es)
EP (1) EP4313037A4 (es)
JP (1) JP2024512069A (es)
KR (1) KR20240004330A (es)
AU (1) AU2022246101A1 (es)
BR (1) BR112023019407A2 (es)
CA (1) CA3213383A1 (es)
IL (1) IL307194A (es)
MX (1) MX2023011240A (es)
WO (1) WO2022204399A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089494A2 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
WO2013156035A1 (en) * 2012-04-18 2013-10-24 Concit Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US10166183B2 (en) * 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
WO2016138138A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
FI4048249T3 (fi) * 2019-10-23 2025-12-05 Maplight Therapeutics Inc Menetelmiä autismikirjon häiriön oireiden hoitamiseksi

Also Published As

Publication number Publication date
KR20240004330A (ko) 2024-01-11
BR112023019407A2 (pt) 2023-11-28
WO2022204399A1 (en) 2022-09-29
EP4313037A4 (en) 2025-02-26
CA3213383A1 (en) 2022-09-29
JP2024512069A (ja) 2024-03-18
US20240189240A1 (en) 2024-06-13
IL307194A (en) 2023-11-01
EP4313037A1 (en) 2024-02-07
AU2022246101A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
NZ784224A (en) Parp1 inhibitors
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
MX2021002322A (es) Nuevos metodos.
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2024003922A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos.
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MY179105A (en) Methods of treating alzheimer's disease
MX2024011254A (es) Moduladores de nlrp3
MX2022000712A (es) Moduladores de nlrp3.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2022011576A (es) Moduladores de nlrp3.
MX2022010868A (es) Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX2023011240A (es) Composiciones farmaceuticas que comprenden zolmitriptan.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.